TD Cowen Sticks to Their Buy Rating for Bio-Techne (TECH)
In a report released today, Kyle Boucher from TD Cowen reiterated a Buy rating on Bio-Techne, with a price target of $65.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
According to TipRanks, Boucher is an analyst with an average return of -3.9% and a 50.00% success rate. Boucher covers the Healthcare sector, focusing on stocks such as Bio-Techne, Myriad Genetics, and Standard BioTools.
Currently, the analyst consensus on Bio-Techne is a Moderate Buy with an average price target of $59.25.
Based on Bio-Techne’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $311.42 million and a net profit of $51.06 million. In comparison, last year the company earned a revenue of $316.18 million and had a net profit of $22.59 million
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TECH in relation to earlier this year. Last month, Amy E. Herr, a Director at TECH sold 6,636.00 shares for a total of $320,386.08.
Read More on TECH:
